Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Communication Channels for Large-Scale Type 2 Diabetes Risk Screening and Intervention Recruitment: Empirical Study.
Jalkanen K, Järvenpää R, Tilles-Tirkkonen T, Martikainen J, Aarnio E, Männikkö R, Rantala E, Karhunen L, Kolehmainen M, Harjumaa M, Poutanen K, Ermes M, Absetz P, Schwab U, Lakka T, Pihlajamäki J, Lindström J; StopDia Study Group. Jalkanen K, et al. Among authors: pihlajamaki j. JMIR Diabetes. 2021 Sep 9;6(3):e21356. doi: 10.2196/21356. JMIR Diabetes. 2021. PMID: 34499036 Free PMC article.
Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study. Kubaszek A, et al. Among authors: pihlajamaki j. Diabetes. 2003 Jul;52(7):1872-6. doi: 10.2337/diabetes.52.7.1872. Diabetes. 2003. PMID: 12829659
The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.
Todorova B, Kubaszek A, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study. Todorova B, et al. Among authors: pihlajamaki j. J Clin Endocrinol Metab. 2004 May;89(5):2019-23. doi: 10.1210/jc.2003-031325. J Clin Endocrinol Metab. 2004. PMID: 15126514 Clinical Trial.
Serum adipokines are associated with cholesterol metabolism in the metabolic syndrome.
Hallikainen M, Kolehmainen M, Schwab U, Laaksonen DE, Niskanen L, Rauramaa R, Pihlajamäki J, Uusitupa M, Miettinen TA, Gylling H. Hallikainen M, et al. Among authors: pihlajamaki j. Clin Chim Acta. 2007 Aug;383(1-2):126-32. doi: 10.1016/j.cca.2007.05.006. Epub 2007 May 18. Clin Chim Acta. 2007. PMID: 17573060
The effectiveness and applicability of different lifestyle interventions for enhancing wellbeing: the study design for a randomized controlled trial for persons with metabolic syndrome risk factors and psychological distress.
Lappalainen R, Sairanen E, Järvelä E, Rantala S, Korpela R, Puttonen S, Kujala UM, Myllymäki T, Peuhkuri K, Mattila E, Kaipainen K, Ahtinen A, Karhunen L, Pihlajamäki J, Järnefelt H, Laitinen J, Kutinlahti E, Saarelma O, Ermes M, Kolehmainen M. Lappalainen R, et al. Among authors: pihlajamaki j. BMC Public Health. 2014 Apr 4;14:310. doi: 10.1186/1471-2458-14-310. BMC Public Health. 2014. PMID: 24708617 Free PMC article. Clinical Trial.
DNA methylation in obesity and type 2 diabetes.
de Mello VD, Pulkkinen L, Lalli M, Kolehmainen M, Pihlajamäki J, Uusitupa M. de Mello VD, et al. Among authors: pihlajamaki j. Ann Med. 2014 May;46(3):103-13. doi: 10.3109/07853890.2013.857259. Epub 2014 Apr 30. Ann Med. 2014. PMID: 24779963 Review.
262 results